Cellect Biotechnology Ltd. (APOP) EPS Estimated At $-0.31

February 20, 2018 - By Marguerite Chambers

 Cellect Biotechnology Ltd. (APOP) EPS Estimated At $ 0.31

Analysts expect Cellect Biotechnology Ltd. (NASDAQ:APOP) to report $-0.31 EPS on March, 22.They anticipate $0.30 EPS change or 3,000.00 % from last quarter’s $-0.01 EPS. After having $-0.39 EPS previously, Cellect Biotechnology Ltd.’s analysts see -20.51 % EPS growth. The stock decreased 3.13% or $0.24 during the last trading session, reaching $7.43. About 70,896 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $48.35 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

More important recent Cellect Biotechnology Ltd. (NASDAQ:APOP) news were published by: Prnewswire.com which released: “Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter …” on August 21, 2017, also Prnewswire.com published article titled: “Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering”, Streetinsider.com published: “Cellect Biotechnology (APOP) Prices IPO at $6.50/ADS” on July 29, 2016. More interesting news about Cellect Biotechnology Ltd. (NASDAQ:APOP) was released by: Prnewswire.com and their article: “Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd …” with publication date: February 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: